FCRC Contract Will Be Completed In Five Parts, Two of Them For Small Business; RFP Available July 24
In Brief: Chabner Names DCT Acting Director, Schepartz Returns To Deputy Job; GM Winners Announced
DCT Board Approves Concepts Of Eight New Biological Response Modifiers Program
FDA Committee Oks AMSA for Group C List, Tables THC Request, Deadlocks On Estramustine NDA
NTP Panel Agrees PBB Carcinogenic, Two Asbestos Varieties Are Not
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition









